| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist
|
Heer, Emily
|
|
|
22 |
11 |
p. 1493-1494
|
artikel
|
| 2 |
A growing vulvar mass in a post-menopausal woman
|
Xie, Youheng
|
|
|
22 |
11 |
p. e530
|
artikel
|
| 3 |
A nodal risk cutoff for whole pelvic radiotherapy for prostate cancer?
|
Murthy, Vedang
|
|
|
22 |
11 |
p. e467
|
artikel
|
| 4 |
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease
|
Elias, Kevin M
|
|
|
22 |
11 |
p. 1490-1491
|
artikel
|
| 5 |
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
|
Saad, Fred
|
|
|
22 |
11 |
p. 1541-1559
|
artikel
|
| 6 |
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
|
Bancroft, Elizabeth K
|
|
|
22 |
11 |
p. 1618-1631
|
artikel
|
| 7 |
British American Tobacco: allegations of malpractice
|
Burki, Talha Khan
|
|
|
22 |
11 |
p. 1501
|
artikel
|
| 8 |
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
|
Cheng, Hongyan
|
|
|
22 |
11 |
p. 1609-1617
|
artikel
|
| 9 |
Cancer care crisis in Nigeria amid doctors' strike
|
Das, Manjulika
|
|
|
22 |
11 |
p. 1502
|
artikel
|
| 10 |
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward
|
Barrios, Carlos H
|
|
|
22 |
11 |
p. e474-e487
|
artikel
|
| 11 |
CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma
|
Nowak, Anna K
|
|
|
22 |
11 |
p. 1485-1487
|
artikel
|
| 12 |
Correction to Lancet Oncol 2021; 22: 1360–62
|
|
|
|
22 |
11 |
p. e472
|
artikel
|
| 13 |
Correction to Lancet Oncol 2020; 21: 763–75
|
|
|
|
22 |
11 |
p. e472
|
artikel
|
| 14 |
Correction to Lancet Oncol 2021; 22: 1468–82
|
|
|
|
22 |
11 |
p. e472
|
artikel
|
| 15 |
Correction to Lancet Oncol 2021; 22: 1573–81
|
|
|
|
22 |
11 |
p. e472
|
artikel
|
| 16 |
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
|
Facon, Thierry
|
|
|
22 |
11 |
p. 1582-1596
|
artikel
|
| 17 |
Drug development in metastatic prostate cancer: lessons from ACIS
|
Swami, Umang
|
|
|
22 |
11 |
p. 1487-1488
|
artikel
|
| 18 |
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
|
|
|
|
22 |
11 |
p. 1507-1517
|
artikel
|
| 19 |
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
|
DiNardo, Courtney D
|
|
|
22 |
11 |
p. 1597-1608
|
artikel
|
| 20 |
Endocrine disruptors—the lessons (not) learned
|
The Lancet Oncology,
|
|
|
22 |
11 |
p. 1483
|
artikel
|
| 21 |
ESMO Congress 2021
|
Lai, Cheryl
|
|
|
22 |
11 |
p. 1499-1500
|
artikel
|
| 22 |
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
|
Yoo, Changhoon
|
|
|
22 |
11 |
p. 1560-1572
|
artikel
|
| 23 |
National cancer control plans across the Eastern Mediterranean region: challenges and opportunities to scale-up
|
Fadhil, Ibtihal
|
|
|
22 |
11 |
p. e517-e529
|
artikel
|
| 24 |
National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis
|
Duggan, Catherine
|
|
|
22 |
11 |
p. 1632-1642
|
artikel
|
| 25 |
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
|
Fennell, Dean A
|
|
|
22 |
11 |
p. 1530-1540
|
artikel
|
| 26 |
Nuclear medicine theranostics comes of age
|
Herrmann, Ken
|
|
|
22 |
11 |
p. 1497-1498
|
artikel
|
| 27 |
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
|
Gao, Jennifer J
|
|
|
22 |
11 |
p. 1573-1581
|
artikel
|
| 28 |
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
|
Werutsky, Gustavo
|
|
|
22 |
11 |
p. e488-e500
|
artikel
|
| 29 |
Poor cancer care in Zimbabwe
|
Das, Manjulika
|
|
|
22 |
11 |
p. 1504
|
artikel
|
| 30 |
Radiotherapy with genomic-adjusted radiation dose
|
Kashihara, Tairo
|
|
|
22 |
11 |
p. e468
|
artikel
|
| 31 |
Radiotherapy with genomic-adjusted radiation dose
|
Musunuru, Hima Bindu
|
|
|
22 |
11 |
p. e469
|
artikel
|
| 32 |
Radiotherapy with genomic-adjusted radiation dose – Authors' reply
|
Scott, Jacob G
|
|
|
22 |
11 |
p. e470-e471
|
artikel
|
| 33 |
Reimagining prostate cancer screening: the IMPACT of germline mutations
|
Gandaglia, Giorgio
|
|
|
22 |
11 |
p. 1491-1492
|
artikel
|
| 34 |
Revisiting neoadjuvant therapy in non-small-cell lung cancer
|
Saw, Stephanie P L
|
|
|
22 |
11 |
p. e501-e516
|
artikel
|
| 35 |
Streamlining the WHO cervical cancer elimination goal
|
Harper, Diane M
|
|
|
22 |
11 |
p. 1484-1485
|
artikel
|
| 36 |
The challenges of inadequate financial support for Australians with cancer
|
Balasubramanian, Adithya
|
|
|
22 |
11 |
p. e473
|
artikel
|
| 37 |
The thin border between individual and collective ethics: the downside of GDPR
|
Cagnazzo, Celeste
|
|
|
22 |
11 |
p. 1494-1496
|
artikel
|
| 38 |
They are our greatest teachers
|
Dee, Edward Christopher
|
|
|
22 |
11 |
p. 1505-1506
|
artikel
|
| 39 |
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer
|
Beal, Eliza W
|
|
|
22 |
11 |
p. 1488-1490
|
artikel
|
| 40 |
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
|
Basu, Partha
|
|
|
22 |
11 |
p. 1518-1529
|
artikel
|
| 41 |
WHO Essential Medicines Committee spotlights unaffordable drugs
|
Furlow, Bryant
|
|
|
22 |
11 |
p. 1503
|
artikel
|
Tijdschrift beschrijving